GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

seniprutug   Click here for help

GtoPdb Ligand ID: 13939

Synonyms: BCD-180 | BCD180
Approved drug Immunopharmacology Ligand
seniprutug is an approved drug
Compound class: Antibody
Comment: Seniprutug (BCD-180) is a monoclonal antibody that targets T cell receptor beta variable 9 (TRBV9) [1]. It induces antibody-dependent cellular cytotoxicity in the target effector T cell population without causing risk of systemic immunosuppression (that would be caused by destroying T cell subsets that are responsible for essential protective functions).
No information available.
Summary of Clinical Use Click here for help
Seniprutug was first approved in 2024 (in Russia) to treat ankylosing spondylitis (Bechterew's disease). Results from a 36 week phase 2 study were published in 2025 [3]. The antibody is in clinical trials in other countries.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05445076 Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis Phase 2 Interventional Biocad
NCT06333210 Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA) Phase 3 Interventional Biocad